Objective: To evaluate the use of MET in ovulation induction and pregnancy rates in a woman with polycystic ovary syndrome (PCOS). Methods:A meta-analysis of randomised clinical trials (RCT) that presented ovulation and gestation rates in women with PCOS, after administering CC or M et al. one or combined was performed. The studies were selected according to the inclusion criteria in PCOS patients, resistant to CC or not. Results:The meta-analysis demonstrated that MET and CC did not significantly increase the ovulation (Odds Ratio 1.72 [0.71, 4.12]) and gestation (OR 1.33 [0.88, 2.02]) rates when compared to the usage of CC itself in women not resistant to CC. However, in women with CC-resistant PCOS, the group treated with CC and MET presented higher rates of ovulation (Odds Ratio = 14.57 [4.96, 42.81]) and gestation (Odds Ratio = 11.86 [2.45, 57.36]) than patients treated only with CC. Conclusion:The combination of MET and CC did not show advantages over the administration of CC alone in women not resistant to CC. However, MET may show satisfactory results in women resistant to CC.

Background: Amphotericin B deoxycholate (d-AmB) is a drug widely used in fungal infections. The adverse effects of this medicine may be acute (infusion-related) or late (cumulative dose-related). Objective: This study aims to evaluate the frequency of adverse reactions to amphotericin B deoxycholate (d-AmB) in adults in a University Hospital, describe the profile of drug use in the institution and evaluate the factors related to the development of reactions with the aid of data mining. Methods: A database with the characteristics of the patients and information about the adverse reactions was created. Then, data mining was performed with the aid of WEKA software. Results: Fifteen adult patients who had used d-AmB in the selected period were identified, being 60% male. The mean age was 41.8 years old. Only 6 patients concluded their treatments with d-AmB, the others had to interrupt the treatment due to some intercurrence. Among the acute phase reactions, the most frequent were vomiting, nausea, phlebitis, hyperthermia and headache, which were related to the drug infusion. As for subacute reactions, the most frequent were urea and creatinine elevation, and hypokalemia. 30 rules were identified after data mining: d-AmB longer-term use, even with normal initial creatinine and urea, they had a greater number of acute reactions; patients with no creatinine change during d-AmB treatment had less subacute reactions; higher number of nephrotoxic drugs use, in those with increased creatinine, they presented a greater number of subacute reactions. Conclusions: The results demonstrate that there is a relation between the time of use and the greater number of adverse reactions. This safety data help clinicians to make decisions.